Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, 14 Kaplan Street, 4920200, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rev Endocr Metab Disord. 2021 Mar;22(1):31-41. doi: 10.1007/s11154-020-09595-0. Epub 2020 Sep 22.
Laron Syndrome (LS) [OMIm#262500], or primary GH insensitivity, was first described in 1966 in consanguineous Jewish families from Yemen. LS is characterized by a typical phenotype that includes dwarfism, obesity and hypogenitalism. The disease is caused by deletions or mutations of the GH-receptor gene, causing high serum GH and low IGF-I serum levels. We studied 75 patients from childhood to adult age. After early hypoglycemia due to the progressive obesity, patients tend to develop glucose intolerance and diabetes. The treatment is by recombinant IGF-I, which improves the height and restores some of the metabolic parameters. An unexpected finding was that patients homozygous for GH-R defects are protected from malignancy lifelong, not so heterozygotes or double heterozygote subjects. We estimate that there are at least 500 patients worldwide, unfortunately only few treated.
拉隆综合征(LS)[OMIm#262500],或原发性 GH 不敏感,于 1966 年首次在也门的近亲犹太家庭中描述。LS 的特征是典型的表型,包括身材矮小、肥胖和性腺发育不全。该疾病是由 GH 受体基因缺失或突变引起的,导致血清 GH 升高和 IGF-I 血清水平降低。我们研究了 75 名从儿童到成年的患者。由于进行性肥胖导致早期低血糖后,患者往往会发展为葡萄糖不耐受和糖尿病。治疗方法是使用重组 IGF-I,这可以改善身高并恢复一些代谢参数。一个意外的发现是,GH-R 缺陷的纯合子患者终生免受恶性肿瘤的影响,而杂合子或双杂合子患者则并非如此。我们估计全世界至少有 500 名患者,但不幸的是只有少数得到了治疗。